Search | Clinical Trials Finder

Conditions: Lupus Nephritis
Interventions: Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more

Conditions: Antibody-mediated Rejection
Interventions: Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more

Conditions: Lupus Nephritis
Interventions: Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 28
States / cities: Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: IgA Nephropathy
Interventions: Mycophenolate Mofetil (MMF), MMF Placebo, ACEi, FOS; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 7 Years to 70 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Myasthenia Gravis Generalised
Interventions: mycophenolate mofetil [CellCept], Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Sun City, Arizona • Sacramento, California • Upland, Pennsylvania

Conditions: Hematopoietic and Lymphatic System Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Renal Transplantation
Interventions: Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more

Conditions: Lupus Nephritis
Interventions: BIIB023, Placebo, mycophenolate mofetil, oral corticosteroids; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Torrance, California • Orlando, Florida • Boston, Massachusetts + 6 more

Conditions: Systemic Sclerosis
Interventions: Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye Disease
Interventions: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Azusa, California • Hemet, California + 33 more

Conditions: Lung Transplant
Interventions: Rituximab (Rituxan®), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 7
States / cities: Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Lupus Nephritis
Interventions: Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Kidney Transplantation
Interventions: CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Lupus Nephritis
Interventions: Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Covina, California • La Jolla, California • Los Angeles, California + 5 more

Conditions: Systemic Lupus Erythematosus
Interventions: Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more

Conditions: Heart Transplantation
Interventions: Daclizumab, Methylprednisolone, Mycophenolate mofetil, Placebo, cyclosporine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more

Conditions: Renal Transplantation
Interventions: Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 53
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more

Conditions: Lupus Nephritis
Interventions: VIB4920, Placebo for VIB4920; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 13 more

Conditions: Scleroderma, Interstitial Lung Disease
Interventions: Mycophenolate mofetil, Cyclophosphamide, Placebo; Drug
Lead sponsor: Michael Roth; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more

Conditions: Systemic Sclerosis
Interventions: Belimumab, Mycophenolate Mofetil, Placebo Infusion; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: mycophenolate mofetil, placebo; Drug
Lead sponsor: Martin, Paul; Other
Eligibility: 4 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 15
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 11 more

Conditions: Age-Related Macular Degeneration
Interventions: Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery; Biological · Drug · Procedure
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pemphigus Vulgaris (PV)
Interventions: Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more

Search by objective public record fields.

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

B Cell Induction in Pediatric Lung Transplantation

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

A Study of Guselkumab in Participants With Active Lupus Nephritis

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

VIBRANT: VIB4920 for Active Lupus Nephritis

Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)